ZM 241385 | Selective A2a adenosine receptor antagonist

CAS:
 139180-30-6
Catalog Number:
 10-4911
ZM 241385 chemical structure

Available Options

Size:PriceQuantity 
5 mg$60.00
25 mg$230.00
Request Quote / Bulk / Custom Size
Product Inquiry

ZM 241385 (139180-30-6) is a potent (IC50 = 33 nM)1 and selective adenosine A2a receptor antagonist.2,3

References/Citations:

  1. Jorg et al. (2015), Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2a and dopamine D2 receptors for the potential treatment of Parkinson’s disease; J. Med. Chem., 58 718
  2. Poucher et al. (1995), The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2A selective adenosine receptor antagonist; Br. J. Pharmacol., 115 1096
  3. Keddie et al. (1996), In vivo characterisation of ZM 241385, a selective adenosine A2A receptor antagonist; Eur. J. Pharmacol., 301 107
139180-30-6, Selective A2a antagonist, Selective adenosine A2a antagonist, Selective adenosine antagonist, ZM 241385 supplier, ZM-241385, ZM241385 supplier
CAS:
139180-30-6
Catalog Number:
10-4911
Activity:
Selective A2a adenosine receptor antagonist
Chemical Names:
4-[2-[[7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol
Molecular Weight:
337.34
Molecular Formula:

C16H15N7O2

Solubility:
Soluble in DMSO (>25 mg/ml)
Physical Properties:
Off-white to beige solid
Purity:

98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

ZM 241385 (139180-30-6) is a potent (IC50 = 33 nM)1 and selective adenosine A2a receptor antagonist.2,3

References/Citations:

  1. Jorg et al. (2015), Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2a and dopamine D2 receptors for the potential treatment of Parkinson’s disease; J. Med. Chem., 58 718
  2. Poucher et al. (1995), The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2A selective adenosine receptor antagonist; Br. J. Pharmacol., 115 1096
  3. Keddie et al. (1996), In vivo characterisation of ZM 241385, a selective adenosine A2A receptor antagonist; Eur. J. Pharmacol., 301 107

STEM CELL

BOGO